High-dose methotrexate and L-asparaginase for the treatment of adult patients with high risk Ph-acute lymphoblastic leukemia

VernacularTitle:大剂量甲氨蝶呤及左旋门冬酰胺酶治疗成年人高危费城染色体阴性急性淋巴细胞白血病
Author: Yue ZHANG ; Hui ZENG ; Juan ZHANG ; Chenxiao FU ; Hebing ZHOU
Publication Type:Journal Article
Keywords: Leukemia,lymphocytic,acute; Methotrexate; L-asparaginase; Long-term survival
From: Journal of Leukemia & Lymphoma 2015;24(12):740-742,745
CountryChina
Language:Chinese
Abstract: Objective To explore the efficacy and safety of high-dose methotrexate (MTX) and L-asparaginase (L-Asp) for the treatment of adult patients with high risk Ph acute lymphoblastic leukemia (ALL).Methods Five adult patients with high risk Ph-ALL were treated with several courses of MTX (3-5 g/m2 by continually intravenous drip for 24 h) and L-Asp (8 000-10 000 U/time, once a day, 10 times for one cycle).Results Five patients were disease-free survival, their survival time was 60-96 months and the median survival time was 73 months.The chemotherapy-related bone marrow depression was mild.No obvious liver and kidney damage, severe allergic reaction and pancreatitis were observed.Conclusion Highdose MTX and L-Asp are effective and well tolerated, and may contribute to long-term survival of adult patients with high risk Ph-ALL.